The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
ApexOnco Front Page
Recent articles
After menin, the company tries again with farnesyl transferase.
Backed by a slender survival signal the industry’s only anti-fucosyl-GM1 MAb is to go pivotal.
Early data suggest that PD-(L)1 x VEGF bispecifics might challenge Keytruda in triple-negative disease.
The small cap biotech Instil Bio tries to follow in Summit’s slipstream.
So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.
Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.
Patients' expression of CEACAM5 might hold the key to activity after all.